- Home
- NCPL vs PALI Comparison
NCPL vs PALI Comparison
Compare NCPL & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- PALI
- Stock Information
- Founded
- NCPL 1984
- PALI 1996
- Country
- NCPL United States
- PALI United States
- Employees
- NCPL N/A
- PALI N/A
- Industry
- NCPL Investment Managers
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCPL Finance
- PALI Health Care
- Exchange
- NCPL Nasdaq
- PALI Nasdaq
- Market Cap
- NCPL 3.9M
- PALI 4.6M
- IPO Year
- NCPL N/A
- PALI N/A
- Fundamental
- Price
- NCPL $2.07
- PALI $1.36
- Analyst Decision
- NCPL
- PALI Strong Buy
- Analyst Count
- NCPL 0
- PALI 2
- Target Price
- NCPL N/A
- PALI $23.00
- AVG Volume (30 Days)
- NCPL 116.3K
- PALI 897.6K
- Earning Date
- NCPL 03-17-2025
- PALI 03-25-2025
- Dividend Yield
- NCPL N/A
- PALI N/A
- EPS Growth
- NCPL N/A
- PALI N/A
- EPS
- NCPL N/A
- PALI N/A
- Revenue
- NCPL $1,702,723.00
- PALI N/A
- Revenue This Year
- NCPL N/A
- PALI N/A
- Revenue Next Year
- NCPL $101.16
- PALI N/A
- P/E Ratio
- NCPL N/A
- PALI N/A
- Revenue Growth
- NCPL N/A
- PALI N/A
- 52 Week Low
- NCPL $1.41
- PALI $1.25
- 52 Week High
- NCPL $22.82
- PALI $9.65
- Technical
- Relative Strength Index (RSI)
- NCPL 57.35
- PALI 36.15
- Support Level
- NCPL $1.99
- PALI $1.25
- Resistance Level
- NCPL $2.12
- PALI $1.65
- Average True Range (ATR)
- NCPL 0.11
- PALI 0.15
- MACD
- NCPL 0.02
- PALI -0.01
- Stochastic Oscillator
- NCPL 89.19
- PALI 17.54
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.